Chris Baugh/LinkedIn
Oct 2, 2026, 11:20
Chris Baugh: Modern ED Strategies for Antithrombotic-Associated Bleeding
Chris Baugh, Chair Elect at Emergency Medicine Foundation, shared a post on LinkedIn:
“New paper in EB Medicine’s Emergency Medicine Practice: ‘Antithrombotic-Associated Bleeding: Management in the Emergency Department,’ co-authored with the incredibly talented Xin Qi and Annie Leamon.
Several points from the review that may change bedside practice:
- Resuscitation and hemorrhage control come first. Reversal runs in parallel and is not the initial priority.
- A normal INR or PTT does not exclude a DOAC effect. Drug-specific anti-factor Xa levels are needed, and a normal thrombin time effectively rules out a clinically significant dabigatran effect.
- Emergent warfarin reversal requires 4F-PCC plus IV vitamin K. Vitamin K alone is insufficient.
- With andexanet withdrawn from the US market, PCC-based replacement is the current strategy for factor Xa inhibitor reversal, though evidence for it remains limited.
- For antiplatelet-associated ICH, platelet transfusion is supported only when neurosurgical intervention is planned. In nonsurgical ICH, it offers no benefit and may cause harm.
- High thrombotic risk, such as a mechanical valve, does not automatically justify or preclude reversal. The decision weighs both risks.
The issue also covers periprocedural management, pregnancy, fibrinolytic reversal, and a clinical pathway for ED use.
It is eligible for 4 AMA PRA Category 1 Credits.”
Stay updated with Hemostasis Today.
-
Nov 19, 2026, 16:27263 PolyU Students and Staff Unite to Donate Blood – Hong Kong Red Cross Blood Transfusion Service
-
Nov 19, 2026, 16:16Billy Otieno: The Future of Blood Donation Lies Beyond Collection
-
Nov 19, 2026, 15:58Hema Goyal: Hematocon 2026 Bringing Together Knowledge, Innovation and Excellence in Hematology
-
Nov 19, 2026, 15:44Chukwuemeka Amarachi: Understanding Complex Blood Grouping Beyond Routine ABO And RhD Typing
-
Nov 19, 2026, 14:19Long-Read Sequencing Is Closing Diagnostic Gaps in Inherited Bleeding Disorders
-
Nov 19, 2026, 13:36Raja Prince: Protein S Silencing and the Future of Hemostatic Therapy
-
Nov 19, 2026, 13:26M. Sekip Altunkan: The Thrombotic Risk of Andexanet Alfa
-
Nov 19, 2026, 13:18Felice Gragnano: Personalizing Antiplatelet Therapy After PCI
-
Nov 19, 2026, 13:11When Postpartum Warning Signs Are Ignored – National Blood Clot Alliance